cached image

Celia A. Schiffer - Publications

Affiliations: 
Biochemistry & Molecular Pharmacology University of Massachusetts Medical School, Worcester, MA, United States 
Area:
Structural basis for molecular recognition in HIV Protease
Website:
http://profiles.umassmed.edu/profiles/ProfileDetails.aspx?From=SE&Person=558

346 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. Journal of Medicinal Chemistry. PMID 34405680 DOI: 10.1021/acs.jmedchem.1c00554  1
2021 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, C Lorenzi JC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, et al. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. PMID 34331873 DOI: 10.1016/j.immuni.2021.07.008  1
2021 Hou S, Lee JM, Myint W, Matsuo H, Yilmaz NK, Schiffer CA. Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s. The Journal of Biological Chemistry. 100909. PMID 34171358 DOI: 10.1016/j.jbc.2021.100909  1
2021 Hou S, Lee JM, Myint W, Matsuo H, Yilmaz NK, Schiffer CA. Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s. The Journal of Biological Chemistry. 100909. PMID 34171358 DOI: 10.1016/j.jbc.2021.100909  1
2021 Leidner F, Kurt Yilmaz N, Schiffer CA. Deciphering Antifungal Drug Resistance in DHFR with Molecular Dynamics and Machine Learning. Journal of Chemical Information and Modeling. 61: 2537-2541. PMID 34138546 DOI: 10.1021/acs.jcim.1c00403  0.01
2021 Leidner F, Kurt Yilmaz N, Schiffer CA. Deciphering Antifungal Drug Resistance in DHFR with Molecular Dynamics and Machine Learning. Journal of Chemical Information and Modeling. 61: 2537-2541. PMID 34138546 DOI: 10.1021/acs.jcim.1c00403  1
2021 Hall MD, Anderson JM, Anderson A, Baker D, Bradner J, Brimacombe KR, Campbell EA, Corbett KS, Carter K, Cherry S, Chiang L, Cihlar T, de Wit E, Denison M, Disney M, ... ... Schiffer CA, et al. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit. The Journal of Infectious Diseases. PMID 34111271 DOI: 10.1093/infdis/jiab305  0.01
2021 Leidner F, Kurt Yilmaz N, Schiffer CA. Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning. Journal of Chemical Theory and Computation. PMID 33783217 DOI: 10.1021/acs.jctc.0c01244  1
2021 Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Biorxiv : the Preprint Server For Biology. PMID 33758864 DOI: 10.1101/2021.03.07.434227  1
2021 Kurt Yilmaz N, Schiffer CA. Introduction: Drug Resistance. Chemical Reviews. 121: 3235-3237. PMID 33757288 DOI: 10.1021/acs.chemrev.1c00118  1
2021 Lockbaum GJ, Henes M, Talledge N, Rusere LN, Kosovrasti K, Nalivaika EA, Somasundaran M, Ali A, Mansky LM, Kurt Yilmaz N, Schiffer CA. Inhibiting HTLV-1 Protease: A Viable Antiviral Target. Acs Chemical Biology. PMID 33619959 DOI: 10.1021/acschembio.0c00975  1
2021 Nichols JC, Schiffer CA, Royer WE. NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP). The Journal of Biological Chemistry. 100351. PMID 33524397 DOI: 10.1016/j.jbc.2021.100351  1
2021 Lockbaum GJ, Reyes AC, Lee JM, Tilvawala R, Nalivaika EA, Ali A, Kurt Yilmaz N, Thompson PR, Schiffer CA. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188. Viruses. 13. PMID 33503819 DOI: 10.3390/v13020174  1
2021 Harshbarger WD, Deming D, Lockbaum GJ, Attatippaholkun N, Kamkaew M, Hou S, Somasundaran M, Wang JP, Finberg RW, Zhu QK, Schiffer CA, Marasco WA. Unique structural solution from a V3-30 antibody targeting the hemagglutinin stem of influenza A viruses. Nature Communications. 12: 559. PMID 33495478 DOI: 10.1038/s41467-020-20879-6  1
2021 Maiti A, Hou S, Schiffer CA, Matsuo H. Interactions of APOBEC3s with DNA and RNA. Current Opinion in Structural Biology. 67: 195-204. PMID 33486429 DOI: 10.1016/j.sbi.2020.12.004  0.01
2021 Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, ... ... Schiffer CA, et al. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Chemical Reviews. PMID 33410674 DOI: 10.1021/acs.chemrev.0c00648  1
2020 Jecrois AM, Dcona MM, Deng X, Bandyopadhyay D, Grossman SR, Schiffer CA, Royer WE. Cryo-EM Structure of CtBP2 Confirms Tetrameric Architecture. Structure (London, England : 1993). PMID 33264605 DOI: 10.1016/j.str.2020.11.008  1
2020 Maiti A, Myint W, Delviks-Frankenberry KA, Hou S, Kanai T, Balachandran V, Sierra Rodriguez C, Tripathi R, Kurt Yilmaz N, Pathak VK, Schiffer CA, Matsuo H. Crystal structure of a soluble APOBEC3G variant suggests ssDNA to bind in a channel that extends between the two domains. Journal of Molecular Biology. PMID 33098858 DOI: 10.1016/j.jmb.2020.10.020  1
2020 Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, Amcheslavsky A, Kurt Yilmaz N, Buttigieg KR, Elmore MJ, Godwin K, Coombes N, Toomey JR, Schneider R, Ramchetty AS, ... ... Schiffer CA, et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nature Communications. 11: 4198. PMID 32826914 DOI: 10.1038/S41467-020-18058-8  1
2020 Cai EP, Ishikawa Y, Zhang W, Leite NC, Li J, Hou S, Kiaf B, Hollister-Lock J, Yilmaz NK, Schiffer CA, Melton DA, Kissler S, Yi P. Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nature Metabolism. PMID 32719542 DOI: 10.1038/s42255-020-0254-1  1
2020 Rusere LN, Lockbaum GJ, Henes M, Lee SK, Spielvogel E, Rao DN, Kosovrasti K, Nalivaika EA, Swanstrom R, Kurt Yilmaz N, Schiffer CA, Ali A. Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-Tetrahydrofuran in a Pseudo-Symmetric Dipeptide Isostere. Journal of Medicinal Chemistry. PMID 32672965 DOI: 10.1021/Acs.Jmedchem.0C00529  1
2020 Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Close BJ, Chen DY, Conway HL, Mohsan S, Cavacini LA, Klempner MS, ... Schiffer CA, et al. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. Biorxiv : the Preprint Server For Biology. PMID 32511396 DOI: 10.1101/2020.05.15.096719  1
2020 Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors. Mbio. 11. PMID 32234812 DOI: 10.1096/Fasebj.2020.34.S1.08779  1
2020 Lockbaum GJ, Leidner F, Royer WE, Kurt Yilmaz N, Schiffer CA. Optimizing the refinement of merohedrally twinned P6 HIV-1 protease-inhibitor cocrystal structures. Acta Crystallographica. Section D, Structural Biology. 76: 302-310. PMID 32133994 DOI: 10.1107/S2059798320001989  1
2020 Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. PMID 32127639 DOI: 10.1038/S41375-020-0776-2  1
2020 Jecrois AM, Bellesis A, Schiffer C, Royer W. Cryo‐EM Structure of CtBP2 Confirms Tetrameric Architecture The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04531  0.01
2020 Hou S, Nalivaika EA, Myint W, Matsuo H, Yilmaz NK, Schiffer CA. Structural Mechanism of Substrate Specificity in Human Cytidine Deaminase Family APOBEC3s The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04501  0.01
2020 Schiffer C. Constraining evolution → avoiding drug resistance: lessons from viruses The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00171  0.01
2020 Royer WE, Nichols JC, Schiffer CA. Illuminating the Structural Determinants for Tetrameric Assembly of Oncogenic CtBP to Guide Inhibitor Design Biophysical Journal. 118: 46a. DOI: 10.1016/J.Bpj.2019.11.430  0.01
2020 Rasapalli S, Reddy Sammeta V, Singh S, Golen JA, Semerdzhiev D, Bo Y, Silby M, Rao R, Ali A, Schiffer CA, Savinov SN. Synthesis and Biological Evaluation of 4/5‐Aroyl‐2‐aminoimidazoles as Microbial Biofilm Inhibitors Chemistryselect. 5: 5965-5969. DOI: 10.1002/slct.202001302  0.01
2019 Whitfield TW, Ragland DA, Zeldovich KB, Schiffer CA. Characterizing protein-ligand binding using atomistic simulation and machine learning: Application to drug resistance in HIV-1 protease. Journal of Chemical Theory and Computation. PMID 31877249 DOI: 10.1021/Acs.Jctc.9B00781  1
2019 Timm J, Kosovrasti K, Henes M, Leidner F, Hou S, Ali A, Kurt Yilmaz N, Schiffer CA. Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir. Acs Chemical Biology. PMID 31868341 DOI: 10.1021/Acschembio.9B00675  1
2019 Solomon WC, Myint W, Hou S, Kanai T, Tripathi R, Kurt Yilmaz N, Schiffer CA, Matsuo H. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA. Nucleic Acids Research. 47: 7676-7689. PMID 31424549 DOI: 10.1093/Nar/Gkz550  1
2019 Rusere LN, Lockbaum GJ, Lee SK, Henes M, Kosovrasti K, Spielvogel E, Nalivaika EA, Swanstrom R, Kurt Yilmaz N, Schiffer CA, Ali A. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands to Optimize Hydrogen Bonding in the Substrate Envelope. Journal of Medicinal Chemistry. PMID 31386368 DOI: 10.1021/Acs.Jmedchem.9B00838  1
2019 Henes M, Kosovrasti K, Lockbaum GJ, Leidner F, Nachum GS, Nalivaika EA, Bolon DNA, Kurt Yilmaz N, Schiffer CA, Whitfield TW. Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance. Biochemistry. PMID 31386353 DOI: 10.1021/Acs.Biochem.9B00446  1
2019 Leidner F, Kurt Yilmaz N, Schiffer CA. Target-Specific Prediction of Ligand Affinity with Structure-Based Interaction Fingerprints. Journal of Chemical Information and Modeling. PMID 31381335 DOI: 10.1021/Acs.Jcim.9B00457  1
2019 Henes M, Lockbaum GJ, Kosovrasti K, Leidner F, Nachum GS, Nalivaika EA, Lee SK, Spielvogel E, Zhou S, Swanstrom R, Bolon DNA, Kurt Yilmaz N, Schiffer CA. pM to µM - Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. Acs Chemical Biology. PMID 31361460 DOI: 10.1021/Acschembio.9B00370  1
2019 Ishima R, Kurt Yilmaz N, Schiffer CA. NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations. Journal of Biomolecular Nmr. PMID 31243634 DOI: 10.1007/S10858-019-00260-6  1
2019 Silvas TV, Schiffer CA. APOBEC3s: DNA-Editing Human Cytidine Deaminases. Protein Science : a Publication of the Protein Society. PMID 31241202 DOI: 10.1002/Pro.3670  1
2019 Lockbaum GJ, Leidner F, Rusere LN, Henes M, Kosovrasti K, Nachum GS, Nalivaika EA, Bolon DNA, Ali A, Kurt Yilmaz N, Schiffer CA. Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. Acs Infectious Diseases. PMID 30990653 DOI: 10.1021/Acsinfecdis.9B00098  1
2019 Özen A, Prachanronarong K, Matthew AN, Soumana DI, Schiffer CA. Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors. Critical Reviews in Biochemistry and Molecular Biology. 1-16. PMID 30821513 DOI: 10.1080/10409238.2019.1568962  1
2019 Boucher JI, Whitfield TW, Dauphin A, Nachum G, Hollins C, Zeldovich KB, Swanstrom R, Schiffer CA, Luban J, Bolon DNA. Constrained mutational sampling of amino acids in HIV-1 protease evolution. Molecular Biology and Evolution. PMID 30721995 DOI: 10.1093/Molbev/Msz022  1
2019 Royer WE, Bellesis AG, Jecrois AM, Hilbert BJ, Dcona MM, Grossman SR, Schiffer CA. Tetrameric Assembly of the Oncogenic C-Terminal Binding Proteins Biophysical Journal. 116: 62a. DOI: 10.1016/J.Bpj.2018.11.380  0.01
2018 Lockbaum GJ, Leidner F, Rusere LN, Henes M, Kosovrasti K, Nachum GS, Nalivaika EA, Ali A, Kurt Yilmaz N, Schiffer CA. Structural Adaptation of Darunavir Analogs Against Primary Mutations in HIV-1 Protease. Acs Infectious Diseases. PMID 30543749 DOI: 10.2210/Pdb6Dh3/Pdb  1
2018 Hou S, Silvas T, Leidner F, Nalivaika EA, Matsuo H, Kurt Yilmaz N, Schiffer CA. Structural analysis of the active site and DNA binding of human cytidine deaminase APOBEC3B. Journal of Chemical Theory and Computation. PMID 30457868 DOI: 10.1021/Acs.Jctc.8B00545  1
2018 Potempa M, Lee SK, KurtYilmaz N, Nalivaika EA, Rogers A, Spielvogel E, Carter CW, Schiffer CA, Swanstrom R. HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites. Journal of Molecular Biology. PMID 30414407 DOI: 10.1016/J.Jmb.2018.10.022  1
2018 Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt-Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, ... ... Schiffer CA, et al. Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody. Journal of Virology. PMID 30381484 DOI: 10.1128/Jvi.01639-18  1
2018 Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA. A call to arms: Unifying the fight against resistance. Science Signaling. 11. PMID 30352947 DOI: 10.1126/Scisignal.Aav0442  0.01
2018 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure (London, England : 1993). PMID 30146168 DOI: 10.1016/J.Str.2018.07.004  1
2018 Rusere LN, Matthew AN, Lockbaum GJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. Acs Medicinal Chemistry Letters. 9: 691-696. PMID 30034602 DOI: 10.1021/Acsmedchemlett.8B00150  1
2018 Moise L, Girard B, Boyle C, Kurt Yilmaz N, Jang H, Schiffer C, Ross T, Martin WD, De Groot AS. T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response. Human Vaccines & Immunotherapeutics. PMID 30015562 DOI: 10.1080/21645515.2018.1495303  1
2018 Maiti A, Myint W, Kanai T, Delviks-Frankenberry K, Sierra Rodriguez C, Pathak VK, Schiffer CA, Matsuo H. Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nature Communications. 9: 2460. PMID 29941968 DOI: 10.1038/S41467-018-04872-8  1
2018 Silvas TV, Hou S, Myint W, Nalivaika E, Somasundaran M, Kelch BA, Matsuo H, Kurt Yilmaz N, Schiffer CA. Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions. Scientific Reports. 8: 7511. PMID 29760455 DOI: 10.1038/S41598-018-25881-Z  1
2018 Bellesis AG, Jecrois AM, Hayes JA, Schiffer C, Royer WE. Assembly of human C-terminal Binding Protein (CtBP) into tetramers. The Journal of Biological Chemistry. PMID 29700119 DOI: 10.1074/Jbc.Ra118.002514  1
2018 Leidner F, Kurt Yilmaz N, Paulsen J, Muller YA, Schiffer CA. Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease. Journal of Chemical Theory and Computation. PMID 29570286 DOI: 10.1021/Acs.Jctc.8B00097  1
2018 Canale AS, Venev SV, Whitfield TW, Caffrey DR, Marasco WA, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Zeldovich KB, Wang JP, Bolon DNA. Synonymous mutations at the beginning of the influenza A virus hemagglutinin gene impact experimental fitness. Journal of Molecular Biology. PMID 29466705 DOI: 10.1016/J.Jmb.2018.02.009  1
2018 Khan SN, Persons JD, Paulsen JL, Guerrero M, Schiffer CA, Kurt-Yilmaz N, Ishima R. Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance. Biochemistry. PMID 29457713 DOI: 10.1021/Acs.Biochem.7B01238  1
2017 Avnir Y, Prachanronarong KL, Zhang Z, Hou S, Peterson EC, Sui J, Zayed H, Kurella VB, McGuire AT, Stamatatos L, Hilbert BJ, Bohn MF, Kowalik TF, Jensen JD, Finberg RW, ... ... Schiffer CA, et al. Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. Cell Reports. 21: 3243-3255. PMID 29241550 DOI: 10.1016/J.Celrep.2017.11.056  1
2017 Matthew AN, Kurt Yilmaz N, Schiffer CA. Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside". Biochemistry. PMID 29192768 DOI: 10.1021/Acs.Biochem.7B01160  1
2017 Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, et al. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078326 DOI: 10.1073/Pnas.1708268114  1
2017 Ragland DA, Whitfield TW, Lee SK, Swanstrom R, Zeldovich KB, Kurt Yilmaz N, Schiffer CA. Elucidating the Interdependence of Drug Resistance from Combinations of Mutations. Journal of Chemical Theory and Computation. PMID 28915040 DOI: 10.1021/Acs.Jctc.7B00601  1
2017 Sun B, Dwivedi N, Bechtel TJ, Paulsen JL, Muth A, Bawadekar M, Li G, Thompson PR, Shelef MA, Schiffer CA, Weerapana E, Ho IC. Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα. Science Immunology. 2. PMID 28783661 DOI: 10.1126/Sciimmunol.Aal3062  1
2017 Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. Journal of Medicinal Chemistry. PMID 28594175 DOI: 10.1021/Acs.Jmedchem.7B00426  1
2017 Kouno T, Silvas TV, Hilbert BJ, Shandilya SMD, Bohn MF, Kelch BA, Royer WE, Somasundaran M, Kurt Yilmaz N, Matsuo H, Schiffer CA. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity. Nature Communications. 8: 15024. PMID 28452355 DOI: 10.1038/Ncomms15024  1
2017 Paulsen JL, Leidner F, Ragland DA, Kurt Yilmaz N, Schiffer CA. Interdependence of Inhibitor Recognition in HIV-1 Protease. Journal of Chemical Theory and Computation. PMID 28358514 DOI: 10.1021/Acs.Jctc.6B01262  1
2017 Lin KH, Ali A, Rusere L, Soumana DI, Yilmaz NK, Schiffer CA. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side. Journal of Virology. PMID 28298600 DOI: 10.1128/Jvi.00045-17  1
2017 Carter CW, Wolfenden R, Schiffer CA, Swanstrom R, Potempa M. Amino acid physical chemistry furnishes a two-dimensional basis set for computational structural biology Acta Crystallographica Section a Foundations and Advances. 73: a299-a299. DOI: 10.1107/S0108767317097070  0.01
2016 Prachanronarong KL, Özen A, Thayer KM, Yilmaz LS, Zeldovich KB, Bolon DN, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Kurt-Yilmaz N, Schiffer CA. Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase. Journal of Chemical Theory and Computation. 12: 6098-6108. PMID 27951676 DOI: 10.1021/Acs.Jctc.6B00703  1
2016 Shandilya S, Kurt Yilmaz N, Sadowski A, Monir E, Schiller ZA, Thomas WD, Klempner MS, Schiffer CA, Wang Y. Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions. Journal of Molecular Recognition : Jmr. PMID 27859766 DOI: 10.1002/Jmr.2595  1
2016 Lin KH, Nalivaika EA, Prachanronarong KL, Yilmaz NK, Schiffer CA. Dengue Protease Substrate Recognition: Binding of the Prime Side. Acs Infectious Diseases. PMID 27657335 DOI: 10.1021/Acsinfecdis.6B00131  1
2016 Soumana DI, Kurt Yilmaz N, Ali A, Prachanronarong KL, Schiffer CA. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. Journal of the American Chemical Society. PMID 27512818 DOI: 10.1021/Jacs.6B06454  1
2016 Schiffer CA. Commentary on: 'Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia'. Leukemia. 30: 1636-1637. PMID 27282253 DOI: 10.1038/Leu.2016.141  0.01
2016 Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends in Microbiology. PMID 27090931 DOI: 10.1016/J.Tim.2016.03.010  1
2016 Schiffer C. Remembering Professor Amy Christine Anderson Cell Chemical Biology. 23: 1041-1042. DOI: 10.1016/J.Chembiol.2016.09.008  0.01
2015 Soumana DI, Kurt Yilmaz N, Prachanronarong KL, Aydin C, Ali A, Schiffer CA. Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. Acs Chemical Biology. PMID 26682473 DOI: 10.1021/Acschembio.5B00647  1
2015 Jiang L, Liu P, Bank C, Renzette N, Prachanronarong K, Yilmaz LS, Caffrey DR, Zeldovich KB, Schiffer CA, Kowalik TF, Jensen JD, Finberg RW, Wang JP, Bolon DN. A balance between inhibitor binding and substrate processing confers influenza drug resistance. Journal of Molecular Biology. PMID 26656922 DOI: 10.1016/J.Jmb.2015.11.027  1
2015 Prabhu P, Shandilya SM, Britan-Rosich E, Nagler A, Schiffer CA, Kotler M. Inhibition of APOBEC3G activity impedes double-stranded DNA repair. The Febs Journal. PMID 26460502 DOI: 10.1111/Febs.13556  1
2015 Nandagopal L, Veeraputhiran M, Jain T, Soubani AO, Schiffer CA. Bronchoscopy can be done safely in patients with thrombocytopenia. Transfusion. PMID 26446048 DOI: 10.1111/trf.13348  1
2015 Ramchandren R, Schiffer CA. Pattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry. Journal of Oncology Practice / American Society of Clinical Oncology. PMID 26349954 DOI: 10.1200/JOP.2015.004523  1
2015 Boopathy S, Silvas TV, Tischbein M, Jansen S, Shandilya SM, Zitzewitz JA, Landers JE, Goode BL, Schiffer CA, Bosco DA. Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proceedings of the National Academy of Sciences of the United States of America. PMID 26056300 DOI: 10.1073/Pnas.1424108112  1
2015 Potempa M, Nalivaika E, Ragland D, Lee SK, Schiffer CA, Swanstrom R. A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. Journal of Molecular Biology. 427: 2360-78. PMID 25986307 DOI: 10.1016/J.Jmb.2015.05.007  1
2015 Kouno T, Luengas EM, Shigematsu M, Shandilya SM, Zhang J, Chen L, Hara M, Schiffer CA, Harris RS, Matsuo H. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nature Structural & Molecular Biology. 22: 485-91. PMID 25984970 DOI: 10.1038/Nsmb.3033  1
2015 Ndjomou J, Corby MJ, Sweeney NL, Hanson AM, Aydin C, Ali A, Schiffer CA, Li K, Frankowski KJ, Schoenen FJ, Frick DN. Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. Acs Chemical Biology. PMID 25961497 DOI: 10.1021/Acschembio.5B00101  1
2015 Bohn MF, Schiffer CA. REdiii: a pipeline for automated structure solution. Acta Crystallographica. Section D, Biological Crystallography. 71: 1059-67. PMID 25945571 DOI: 10.1107/S139900471500303X  1
2015 Bohn MF, Shandilya SM, Silvas TV, Nalivaika EA, Kouno T, Kelch BA, Ryder SP, Kurt-Yilmaz N, Somasundaran M, Schiffer CA. The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. Structure (London, England : 1993). 23: 903-11. PMID 25914058 DOI: 10.1016/J.Str.2015.03.016  1
2015 Zeldovich KB, Liu P, Renzette N, Foll M, Pham ST, Venev SV, Gallagher GR, Bolon DN, Kurt-Jones EA, Jensen JD, Caffrey DR, Schiffer CA, Kowalik TF, Wang JP, Finberg RW. Positive Selection Drives Preferred Segment Combinations during Influenza Virus Reassortment. Molecular Biology and Evolution. 32: 1519-32. PMID 25713211 DOI: 10.1093/Molbev/Msv044  1
2015 Özer N, Özen A, Schiffer CA, Halilo?lu T. Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution. Evolutionary Applications. 8: 185-98. PMID 25685193 DOI: 10.1111/Eva.12241  1
2015 Hilbert BJ, Morris BL, Ellis KC, Paulsen JL, Schiffer CA, Grossman SR, Royer WE. Structure-guided design of a high affinity inhibitor to human CtBP. Acs Chemical Biology. 10: 1118-27. PMID 25636004 DOI: 10.1021/Cb500820B  1
2015 Kouno T, Luengas E, Shigematu M, Shandilya S, Zhang J, Chen L, Hara M, Schiffer C, Harris R, Matsuo H. 1H, 13C, 15N chemical shift assignments for APOBEC3G NTD variant, sNTD Journal of Back and Musculoskeletal Rehabilitation. DOI: 10.13018/Bmr25509  1
2014 Zhou H, Li S, Badger J, Nalivaika E, Cai Y, Foulkes-Murzycki J, Schiffer C, Makowski L. Modulation of HIV protease flexibility by the T80N mutation. Proteins. PMID 25488402 DOI: 10.1002/Prot.24737  1
2014 Shandilya SM, Bohn MF, Schiffer CA. A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. Virology. 471: 105-16. PMID 25461536 DOI: 10.1016/J.Virol.2014.09.023  1
2014 Schiffer CA. Optimal dose and schedule of consolidation in AML: is there a standard? Best Practice & Research. Clinical Haematology. 27: 259-64. PMID 25455275 DOI: 10.1016/j.beha.2014.10.007  1
2014 Özen A, Lin KH, Kurt Yilmaz N, Schiffer CA. Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proceedings of the National Academy of Sciences of the United States of America. 111: 15993-8. PMID 25355911 DOI: 10.1073/Pnas.1414063111  1
2014 Schiffer CA. They took a mulligan and mostly got it right … the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation. Transfusion. 54: 2372-4. PMID 25302734 DOI: 10.1111/trf.12821  1
2014 Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. Acs Chemical Biology. 9: 2485-90. PMID 25243902 DOI: 10.1021/Cb5006118  1
2014 Cai Y, Myint W, Paulsen JL, Schiffer CA, Ishima R, Kurt Yilmaz N. Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease. Journal of Chemical Theory and Computation. 10: 3438-3448. PMID 25136270 DOI: 10.1021/Ct4010454  1
2014 Ragland DA, Nalivaika EA, Nalam MN, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. Journal of the American Chemical Society. 136: 11956-63. PMID 25091085 DOI: 10.1021/Ja504096M  1
2014 Kolli M, Ozen A, Kurt-Yilmaz N, Schiffer CA. HIV-1 protease-substrate coevolution in nelfinavir resistance. Journal of Virology. 88: 7145-54. PMID 24719428 DOI: 10.1128/Jvi.00266-14  1
2014 Hilbert BJ, Grossman SR, Schiffer CA, Royer WE. Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design. Febs Letters. 588: 1743-8. PMID 24657618 DOI: 10.1016/J.Febslet.2014.03.026  1
2014 Foll M, Poh YP, Renzette N, Ferrer-Admetlla A, Bank C, Shim H, Malaspinas AS, Ewing G, Liu P, Wegmann D, Caffrey DR, Zeldovich KB, Bolon DN, Wang JP, Kowalik TF, ... Schiffer CA, et al. Influenza virus drug resistance: a time-sampled population genetics perspective. Plos Genetics. 10: e1004185. PMID 24586206 DOI: 10.1371/Journal.Pgen.1004185  1
2014 Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 123: 2317-24. PMID 24569263 DOI: 10.1182/Blood-2013-10-532341  1
2014 Renzette N, Caffrey DR, Zeldovich KB, Liu P, Gallagher GR, Aiello D, Porter AJ, Kurt-Jones EA, Bolon DN, Poh YP, Jensen JD, Schiffer CA, Kowalik TF, Finberg RW, Wang JP. Evolution of the influenza A virus genome during development of oseltamivir resistance in vitro. Journal of Virology. 88: 272-81. PMID 24155392 DOI: 10.1128/Jvi.01067-13  1
2014 Schiffer C. Combatting Drug Resistance: Lessons from the viral proteases of HIV and HCV Acta Crystallographica Section a Foundations and Advances. 70: C116-C116. DOI: 10.1107/S2053273314098830  0.01
2014 Yang J, Bentley G, Schiffer CA. Pitfalls in the Diagnosis of Myelodysplastic Syndromes Cancer Consult: Expertise For Clinical Practice. 97-105. DOI: 10.1002/9781118589199.ch14  1
2013 Ozen A, Sherman W, Schiffer CA. Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design. Journal of Chemical Theory and Computation. 9: 5693-5705. PMID 24587770 DOI: 10.1021/Ct400603P  1
2013 Cheng N, Lee SK, Donover PS, Reichman M, Schiffer CA, Hull-Ryde EA, Swanstrom R, Janzen WP. Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs. Journal of Laboratory Automation. 19: 297-303. PMID 24305957 DOI: 10.1177/2211068213513453  1
2013 Silver NW, King BM, Nalam MN, Cao H, Ali A, Kiran Kumar Reddy GS, Rana TM, Schiffer CA, Tidor B. Efficient Computation of Small-Molecule Configurational Binding Entropy and Free Energy Changes by Ensemble Enumeration. Journal of Chemical Theory and Computation. 9: 5098-5115. PMID 24250277 DOI: 10.1021/Ct400383V  1
2013 Schiffer CA. First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice. Oncology (Williston Park, N.Y.). 27: 780, 825. PMID 24133825  1
2013 Aydin C, Mukherjee S, Hanson AM, Frick DN, Schiffer CA. The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities. Protein Science : a Publication of the Protein Society. 22: 1786-98. PMID 24123290 DOI: 10.1002/Pro.2378  1
2013 Nalam MN, Ali A, Reddy GS, Cao H, Anjum SG, Altman MD, Yilmaz NK, Tidor B, Rana TM, Schiffer CA. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chemistry & Biology. 20: 1116-24. PMID 24012370 DOI: 10.1016/J.Chembiol.2013.07.014  1
2013 Shen Y, Altman MD, Ali A, Nalam MN, Cao H, Rana TM, Schiffer CA, Tidor B. Testing the substrate-envelope hypothesis with designed pairs of compounds. Acs Chemical Biology. 8: 2433-41. PMID 23952265 DOI: 10.1021/Cb400468C  1
2013 Schiffer C. Interview with celia schiffer Future Medicinal Chemistry. 5: 1193-1197. PMID 23859201 DOI: 10.4155/Fmc.13.106  1
2013 Schiffer CA. Haematological cancer: Prophylactic platelet transfusion is frequently not necessary. Nature Reviews. Clinical Oncology. 10: 431-2. PMID 23820637 DOI: 10.1038/nrclinonc.2013.113  1
2013 Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW. Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1. Antimicrobial Agents and Chemotherapy. PMID 23796938 DOI: 10.1128/Aac.00614-13  1
2013 Lee SK, Cheng N, Hull-Ryde E, Potempa M, Schiffer CA, Janzen W, Swanstrom R. A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid. Biochemistry. 52: 4929-40. PMID 23763575 DOI: 10.1021/Bi4005232  1
2013 Bohn MF, Shandilya SM, Albin JS, Kouno T, Anderson BD, McDougle RM, Carpenter MA, Rathore A, Evans L, Davis AN, Zhang J, Lu Y, Somasundaran M, Matsuo H, Harris RS, ... Schiffer CA, et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure (London, England : 1993). 21: 1042-50. PMID 23685212 DOI: 10.1016/J.Str.2013.04.010  1
2013 Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. Acs Chemical Biology. 8: 1469-78. PMID 23594083 DOI: 10.1021/Cb400100G  1
2013 Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman MS. All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. Leukemia Research. 37: 795-801. PMID 23528262 DOI: 10.1016/j.leukres.2013.03.001  1
2013 Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, Gorman M, Ligibel J, Mansfield P, Levine M. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1357-70. PMID 23460705 DOI: 10.1200/JCO.2012.45.5733  1
2013 Schiffer CA. If at first you don't succeed: stem-cell transplantation for acute myeloid leukemia after first relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1259-61. PMID 23439749 DOI: 10.1200/JCO.2012.43.4241  1
2013 Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet (London, England). 381: 484-95. PMID 23399072 DOI: 10.1016/S0140-6736(12)61727-9  1
2013 Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50. Journal of Virology. 87: 4176-84. PMID 23365446 DOI: 10.1128/Jvi.03486-12  1
2013 Foulkes-Murzycki JE, Rosi C, Kurt Yilmaz N, Shafer RW, Schiffer CA. Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. Acs Chemical Biology. 8: 513-8. PMID 23252515 DOI: 10.1021/Cb3006193  1
2013 Babrzadeh F, Varghese V, Pacold M, Liu TF, Nyrén P, Schiffer C, Fessel WJ, Shafer RW. Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance Journal of Antimicrobial Chemotherapy. 68: 414-418. PMID 23085775 DOI: 10.1093/Jac/Dks409  1
2013 Liu CY, Chandrasekar PH, Masood A, Schiffer CA. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 19: 18-23. PMID 22635416 DOI: 10.1177/1078155212447975  1
2013 Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, Leonard B, Shandilya SM, Bohn M, Schiffer CA, Brown WL, Harris RS. 116 Deamination of both methyl- and normal-cytosine by the foreign DNA restriction enzyme APOBEC3A Journal of Biomolecular Structure and Dynamics. 31: 74-74. DOI: 10.1080/07391102.2013.786358  0.01
2013 Schiffer CA. Supportive care for patients with leukemia: A historical perspective Neoplastic Diseases of the Blood. 1141-1147. DOI: 10.1007/978-1-4614-3764-2_50  1
2012 Ozen A, Halilo?lu T, Schiffer CA. HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern. Journal of Chemical Theory and Computation. 8. PMID 24348205 DOI: 10.1021/Ct200668A  1
2012 Schiffer CA. Which TKI should be recommended as initial treatment for CML in chronic phase? Oncology (Williston Park, N.Y.). 26: 912, 914. PMID 23175997  1
2012 Cai Y, Yilmaz NK, Myint W, Ishima R, Schiffer CA. Differential Flap Dynamics in Wild-type and a Drug Resistant Variant of HIV-1 Protease Revealed by Molecular Dynamics and NMR Relaxation. Journal of Chemical Theory and Computation. 8: 3452-3462. PMID 23144597 DOI: 10.1021/Ct300076Y  1
2012 Yang J, Schiffer CA. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? Expert Review of Hematology. 5: 395-407. PMID 22992234 DOI: 10.1586/ehm.12.32  1
2012 Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM. Gemtuzumab ozogamicin: time to resurrect? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3921-3. PMID 22987091 DOI: 10.1200/JCO.2012.43.0132  1
2012 Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. Plos Pathogens. 8: e1002832. PMID 22910833 DOI: 10.1371/Journal.Ppat.1002832  1
2012 Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, Leonard B, Shandilya SM, Bohn MF, Schiffer CA, Brown WL, Harris RS. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. The Journal of Biological Chemistry. 287: 34801-8. PMID 22896697 DOI: 10.1074/Jbc.M112.385161  1
2012 Mruk K, Shandilya SM, Blaustein RO, Schiffer CA, Kobertz WR. Structural insights into neuronal K+ channel-calmodulin complexes. Proceedings of the National Academy of Sciences of the United States of America. 109: 13579-83. PMID 22869708 DOI: 10.1073/Pnas.1207606109  1
2012 Auclair JR, Somasundaran M, Green KM, Evans JE, Schiffer CA, Ringe D, Petsko GA, Agar JN. Mass spectrometry tools for analysis of intermolecular interactions. Methods in Molecular Biology (Clifton, N.J.). 896: 387-98. PMID 22821539 DOI: 10.1007/978-1-4614-3704-8_26  1
2012 King NM, Prabu-Jeyabalan M, Bandaranayake RM, Nalam MN, Nalivaika EA, Özen A, Halilo?lu T, Yilmaz NK, Schiffer CA. Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. Acs Chemical Biology. 7: 1536-46. PMID 22712830 DOI: 10.1021/Cb300191K  1
2012 Parai MK, Huggins DJ, Cao H, Nalam MN, Ali A, Schiffer CA, Tidor B, Rana TM. Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance. Journal of Medicinal Chemistry. 55: 6328-41. PMID 22708897 DOI: 10.1021/Jm300238H  1
2012 Stone RM, Fischer T, Paquette R, Schiller G, Schiffer CA, Ehninger G, Cortes J, Kantarjian HM, DeAngelo DJ, Huntsman-Labed A, Dutreix C, del Corral A, Giles F. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 26: 2061-8. PMID 22627678 DOI: 10.1038/Leu.2012.115  1
2012 Alvizo O, Mittal S, Mayo SL, Schiffer CA. Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease. Protein Science : a Publication of the Protein Society. 21: 1029-41. PMID 22549928 DOI: 10.1002/Pro.2086  1
2012 Myint W, Cai Y, Schiffer CA, Ishima R. Quantitative comparison of errors in 15N transverse relaxation rates measured using various CPMG phasing schemes. Journal of Biomolecular Nmr. 53: 13-23. PMID 22466935 DOI: 10.1007/S10858-012-9621-X  1
2012 Lee SK, Potempa M, Kolli M, Özen A, Schiffer CA, Swanstrom R. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. The Journal of Biological Chemistry. 287: 13279-90. PMID 22334652 DOI: 10.1074/Jbc.M112.339374  1
2012 Mittal S, Cai Y, Nalam MN, Bolon DN, Schiffer CA. Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease. Journal of the American Chemical Society. 134: 4163-8. PMID 22295904 DOI: 10.1021/Ja2095766  1
2012 Cai Y, Schiffer C. Decomposing the energetic impact of drug-resistant mutations: The example of HIV-1 protease-DRV binding Methods in Molecular Biology. 819: 551-560. PMID 22183557 DOI: 10.1007/978-1-61779-465-0_32  1
2012 Li M, Shandilya SM, Carpenter MA, Rathore A, Brown WL, Perkins AL, Harki DA, Solberg J, Hook DJ, Pandey KK, Parniak MA, Johnson JR, Krogan NJ, Somasundaran M, Ali A, ... Schiffer CA, et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. Acs Chemical Biology. 7: 506-17. PMID 22181350 DOI: 10.1021/Cb200440Y  1
2012 Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica. 97: 739-42. PMID 22133771 DOI: 10.3324/haematol.2011.055822  1
2012 Mruk K, Shandilya SM, Blaustein RO, Schiffer CA, Kobertz WR. Structural Insights into Calmodulation of Neuronal KCNQ Channels Biophysical Journal. 102: 13a-14a. DOI: 10.1016/J.Bpj.2011.11.098  0.01
2011 Schiffer CA. What to do if there is no evidence? The issue of surgical procedures in patients with thrombocytopenia. Transfusion. 51: 2262-4. PMID 22023181 DOI: 10.1111/j.1537-2995.2011.03409.x  1
2011 Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrobial Agents and Chemotherapy. 55: 5723-31. PMID 21896904 DOI: 10.1128/Aac.00748-11  1
2011 Vay A, Kumar S, Seward S, Semaan A, Schiffer CA, Munkarah AR, Morris RT. Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis. Gynecologic Oncology. 123: 456-60. PMID 21855120 DOI: 10.1016/j.ygyno.2011.07.097  1
2011 Anderson AC, Pollastri MP, Schiffer CA, Peet NP. The challenge of developing robust drugs to overcome resistance. Drug Discovery Today. 16: 755-61. PMID 21784168 DOI: 10.1016/J.Drudis.2011.07.001  1
2011 Ozen A, Halilo?lu T, Schiffer CA. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. Journal of Molecular Biology. 410: 726-44. PMID 21762811 DOI: 10.1016/J.Jmb.2011.03.053  1
2011 Romano KP, Laine JM, Deveau LM, Cao H, Massi F, Schiffer CA. Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. Journal of Virology. 85: 6106-16. PMID 21507982 DOI: 10.1128/Jvi.00377-11  1
2011 Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity Antimicrobial Agents and Chemotherapy. 55: 1106-1113. PMID 21149628 DOI: 10.1128/Aac.01228-10  1
2011 Valent J, Schiffer CA. Thrombocytopenia and platelet transfusions in patients with cancer. Cancer Treatment and Research. 157: 251-65. PMID 21052961 DOI: 10.1007/978-1-4419-7073-2_15  1
2011 Norkin M, Uberti JP, Schiffer CA. Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leukemia Research. 35: 139-44. PMID 20970853 DOI: 10.1016/j.leukres.2010.09.016  1
2011 Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leukemia Research. 35: e1-3. PMID 20888043 DOI: 10.1016/j.leukres.2010.08.022  1
2011 Romano KP, Laine JM, Deveau LM, Cao H, Massi F, Schiffer CA. Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease Journal of Virology. DOI: 10.2210/Pdb3Rc4/Pdb  1
2011 Straza MW, Kovi RC, Paliwal S, Rajeshkumar B, Hilbert B, Doughty T, Parker D, Royer W, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Abstract 1633: C-terminal binding proteins are novel drug targets Cancer Research. 71: 1633-1633. DOI: 10.1158/1538-7445.Am2011-1633  1
2010 Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MN, Nalivaika EA, Ozen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA. Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses. 2: 2509-35. PMID 21994628 DOI: 10.3390/V2112509  1
2010 Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proceedings of the National Academy of Sciences of the United States of America. 107: 20986-91. PMID 21084633 DOI: 10.1073/Pnas.1006370107  1
2010 Schiffer CA. CML: how low can you go? Blood. 116: 3686-7. PMID 21071610 DOI: 10.1182/blood-2010-08-302323  1
2010 Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Schiffer CA, Rana TM. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. Journal of Medicinal Chemistry. 53: 7699-708. PMID 20958050 DOI: 10.1021/Jm1008743  1
2010 Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle (Georgetown, Tex.). 9: 3740-50. PMID 20930544 DOI: 10.4161/Cc.9.18.12936  1
2010 Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, ... ... Schiffer CA, et al. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116: 5650-9. PMID 20858857 DOI: 10.1182/blood-2010-06-288613  1
2010 Ozer N, Schiffer CA, Haliloglu T. Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. Biophysical Journal. 99: 1650-9. PMID 20816079 DOI: 10.1016/J.Bpj.2010.06.064  1
2010 Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. Journal of Virology. 84: 9995-10003. PMID 20660190 DOI: 10.1128/Jvi.00505-10  1
2010 Cai Y, Schiffer CA. Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV. Journal of Chemical Theory and Computation. 6: 1358-1368. PMID 20543885 DOI: 10.1021/Ct9004678  1
2010 Norkin M, Schiffer CA. Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value? Current Hematologic Malignancy Reports. 5: 88-94. PMID 20425401 DOI: 10.1007/s11899-010-0046-x  1
2010 Nalam MN, Ali A, Altman MD, Reddy GS, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, Rana TM, Schiffer CA. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. Journal of Virology. 84: 5368-78. PMID 20237088 DOI: 10.1128/Jvi.02531-09  1
2010 Shandilya SM, Nalam MN, Nalivaika EA, Gross PJ, Valesano JC, Shindo K, Li M, Munson M, Royer WE, Harjes E, Kono T, Matsuo H, Harris RS, Somasundaran M, Schiffer CA. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure (London, England : 1993). 18: 28-38. PMID 20152150 DOI: 10.1016/J.Str.2009.10.016  1
2010 Schiffer CA. "I am older, not elderly," said the patient with acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 521-3. PMID 20026796 DOI: 10.1200/JCO.2009.25.8616  1
2010 Saglio G, Cortes JE, Schiffer CA, Coutre Pl, Jabbour E, Bahceci E, Lambert A, Shah NP. Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy. Journal of Clinical Oncology. 28: 6569-6569. DOI: 10.1200/Jco.2010.28.15_Suppl.6569  1
2010 Schiffer CA, Cortes JE, Saglio G, Coutre Pl, Bahceci E, Dejardin D, Shah NP. Association of lymphocytosis following treatment with dasatinib with response and outcome. Journal of Clinical Oncology. 28: 6553-6553. DOI: 10.1200/Jco.2010.28.15_Suppl.6553  1
2010 Roy A, Shah NP, Coutre Pl, Wang X, Schiffer CA, Saglio G, Lambert A, Damokosh A, Bahceci E, Cortes JE. Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients. Journal of Clinical Oncology. 28: 6518-6518. DOI: 10.1200/Jco.2010.28.15_Suppl.6518  1
2010 Shah NP, Cortes JE, Schiffer CA, Coutre Pl, Bahceci E, Lambert A, Saglio G. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. Journal of Clinical Oncology. 28: 6512-6512. DOI: 10.1200/Jco.2010.28.15_Suppl.6512  1
2009 Ramchandren R, Schiffer CA. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia. Biologics : Targets & Therapy. 3: 205-14. PMID 19707409 DOI: 10.2147/BTT.S3791  1
2009 Kolli M, Stawiski E, Chappey C, Schiffer CA. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. Journal of Virology. 83: 11027-42. PMID 19706699 DOI: 10.1128/Jvi.00628-09  1
2009 Kairys V, Gilson MK, Lather V, Schiffer CA, Fernandes MX. Toward the design of mutation-resistant enzyme inhibitors: further evaluation of the substrate envelope hypothesis. Chemical Biology & Drug Design. 74: 234-45. PMID 19703025 DOI: 10.1111/J.1747-0285.2009.00851.X  1
2009 Jorissen RN, Reddy GS, Ali A, Altman MD, Chellappan S, Anjum SG, Tidor B, Schiffer CA, Rana TM, Gilson MK. Additivity in the analysis and design of HIV protease inhibitors. Journal of Medicinal Chemistry. 52: 737-54. PMID 19193159 DOI: 10.1021/Jm8009525  1
2009 Anderson J, Schiffer C, Lee SK, Swanstrom R. Viral protease inhibitors. Handbook of Experimental Pharmacology. 85-110. PMID 19048198 DOI: 10.1007/978-3-540-79086-0_4  1
2009 Srinivasan S, Schiffer CA. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leukemia Research. 33: 561-4. PMID 18676017 DOI: 10.1016/j.leukres.2008.06.024  1
2009 Ozen A, Haliloglu T, Schiffer CA. Using Molecular Dynamics to Investigate Substrate Recognition and Co-evolution in HIV-1 Protease Biophysical Journal. 96: 598a. DOI: 10.1016/J.Bpj.2008.12.3129  0.01
2009 Royer WE, Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K. Activation Of Interferon Regulatory Factors Revealed By The Crystal Structure Of Dimeric IRF-5 Biophysical Journal. 96: 586a-587a. DOI: 10.1016/J.Bpj.2008.12.3070  0.01
2009 Bandaranayake RM, Kolli M, Prabu-Jeyabalan M, Nalam M, Ng C, Kakizawa J, Heroux A, King NM, Sugiura W, Schiffer CA. Structural Explanations to Altered Drug Resistance Pathways in HIV-1 Non-Clade B Proteases Biophysical Journal. 96: 447a. DOI: 10.1016/J.Bpj.2008.12.2298  0.01
2009 Mittal S, Schiffer CA. Protein Engineering as a tool For Probing Potential Protein Dynamics in HIV-1 Protease Biophysical Journal. 96: 321a. DOI: 10.1016/J.Bpj.2008.12.1609  0.01
2008 Nalam MN, Schiffer CA. New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Current Opinion in Hiv and Aids. 3: 642-6. PMID 19373036 DOI: 10.1097/Coh.0B013E3283136Cee  1
2008 Schiffer CA. Molecular characterization of AML: a significant advance or just another prognostic factor? Best Practice & Research. Clinical Haematology. 21: 621-8. PMID 19041601 DOI: 10.1016/j.beha.2008.08.006  1
2008 Pawa S, Khalifa AJ, Ehrinpreis MN, Schiffer CA, Siddiqui FA. Zinc toxicity from massive and prolonged coin ingestion in an adult. The American Journal of the Medical Sciences. 336: 430-3. PMID 19011402 DOI: 10.1097/MAJ.0b013e31815f2c05  1
2008 Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K, Royer WE. Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nature Structural & Molecular Biology. 15: 1213-20. PMID 18836453 DOI: 10.1038/Nsmb.1496  1
2008 Lefebvre E, Schiffer CA. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. Aids Reviews. 10: 131-42. PMID 18820715  1
2008 Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opinion On Pharmacotherapy. 9: 1667-78. PMID 18570600 DOI: 10.1517/14656566.9.10.1667  1
2008 Chen W, Srinath H, Lam SS, Schiffer CA, Royer WE, Lin K. Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. Journal of Molecular Biology. 379: 251-60. PMID 18440553 DOI: 10.1016/J.Jmb.2008.03.050  1
2008 Bandaranayake RM, Prabu-Jeyabalan M, Kakizawa J, Sugiura W, Schiffer CA. Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6. Journal of Virology. 82: 6762-6. PMID 18434392 DOI: 10.1128/Jvi.00018-08  1
2008 Altman MD, Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Chellappan S, Kairys V, Fernandes MX, Gilson MK, Schiffer CA, Rana TM, Tidor B. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. Journal of the American Chemical Society. 130: 6099-113. PMID 18412349 DOI: 10.1021/Ja076558P  1
2008 Sahay T, Schiffer CA. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors. Current Opinion in Hematology. 15: 134-9. PMID 18300760 DOI: 10.1097/MOH.0b013e3282f42898  1
2008 Schiffer CA. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Seminars in Hematology. 45: 3-7. PMID 18179963 DOI: 10.1053/j.seminhematol.2007.10.002  1
2008 Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 111: 1039-43. PMID 17932248 DOI: 10.1182/Blood-2007-07-103523  1
2008 Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 111: 86-93. PMID 17893227 DOI: 10.1182/Blood-2007-01-068833  1
2008 Altman MD, Nalivaika EA, Prabu-Jeyabalan M, Schiffer CA, Tidor B. Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease. Proteins. 70: 678-94. PMID 17729291 DOI: 10.1002/Prot.21514  1
2008 Schiffer CA. Second-generation TKIs in chronic myelogenous leukemia Oncology. 22: 446-448.  1
2007 Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Nathans RS, Schiffer CA, Rana TM. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. Journal of Medicinal Chemistry. 50: 4316-28. PMID 17696512 DOI: 10.1021/Jm070284Z  1
2007 Schiffer CA. Advances in MDS Clinical Advances in Hematology and Oncology. 5: 450-452. PMID 17679919  1
2007 Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia New England Journal of Medicine. 357: 258-265. PMID 17634461 DOI: 10.1056/NEJMct071828  1
2007 Auclair JR, Green KM, Shandilya S, Evans JE, Somasundaran M, Schiffer CA. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins. 69: 270-84. PMID 17598142 DOI: 10.1002/Prot.21471  1
2007 Nalam MN, Peeters A, Jonckers TH, Dierynck I, Schiffer CA. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease. Journal of Virology. 81: 9512-8. PMID 17596316 DOI: 10.1128/Jvi.00799-07  1
2007 Chellappan S, Kiran Kumar Reddy GS, Ali A, Nalam MN, Anjum SG, Cao H, Kairys V, Fernandes MX, Altman MD, Tidor B, Rana TM, Schiffer CA, Gilson MK. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chemical Biology & Drug Design. 69: 298-313. PMID 17539822 DOI: 10.1111/J.1747-0285.2007.00514.X  1
2007 Chellappan S, Kairys V, Fernandes MX, Schiffer C, Gilson MK. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Proteins. 68: 561-7. PMID 17474129 DOI: 10.1002/Prot.21431  1
2007 Schiffer CA. Myelodysplasia: The good, the fair and the ugly Best Practice and Research: Clinical Haematology. 20: 49-55. PMID 17336254 DOI: 10.1016/j.beha.2006.12.001  1
2007 Foulkes-Murzycki JE, Scott WR, Schiffer CA. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure (London, England : 1993). 15: 225-33. PMID 17292840 DOI: 10.1016/J.Str.2007.01.006  1
2007 Chen W, Lam SS, Srinath H, Schiffer CA, Royer WE, Lin K. Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling. The Journal of Biological Chemistry. 282: 11365-76. PMID 17283070 DOI: 10.1074/Jbc.M700186200  1
2007 Atallah E, Schiffer CA. Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): Is there a link? Leukemia Research. 31: 720-721. PMID 16956658 DOI: 10.1016/j.leukres.2006.06.025  1
2007 Schiffer CA. What if conventional-dose imatinib fails? Blood. 109: 5068-5069. DOI: 10.1182/blood-2007-04-081794  1
2007 Schiffer CA, George SL. Haematologic Cancers: Challenges in Developing New Therapeutic Approaches Textbook of Clinical Trials: Second Edition. 167-175. DOI: 10.1002/9780470010167.ch12  1
2007 Schiffer CA. Combating drug resistance-identifying resilient molecular targets and robust drugs Rsc Biomolecular Sciences. 127-133.  1
2007 Schiffer CA. The author replies [6] New England Journal of Medicine. 357: 1557-1558.  1
2006 Zonder JA, Schiffer CA. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate Current Hematologic Malignancy Reports. 1: 141-151. PMID 20425345 DOI: 10.1007/s11899-996-0002-y  1
2006 Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. Aids Research and Human Retroviruses. 22: 1300-5. PMID 17209774 DOI: 10.1089/Aid.2006.22.1300  1
2006 Ali A, Reddy GS, Cao H, Anjum SG, Nalam MN, Schiffer CA, Rana TM. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. Journal of Medicinal Chemistry. 49: 7342-56. PMID 17149864 DOI: 10.1021/Jm060666P  1
2006 Schiffer CA. Clinical issues in the management of patients with myelodysplasia Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 205-210. PMID 17124062  1
2006 Forget AL, Kudron MM, McGrew DA, Calmann MA, Schiffer CA, Knight KL. RecA dimers serve as a functional unit for assembly of active nucleoprotein filaments. Biochemistry. 45: 13537-42. PMID 17087507 DOI: 10.1021/Bi060938Q  1
2006 Foulkes JE, Prabu-Jeyabalan M, Cooper D, Henderson GJ, Harris J, Swanstrom R, Schiffer CA. Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. Journal of Virology. 80: 6906-16. PMID 16809296 DOI: 10.1128/Jvi.01900-05  1
2006 Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Biology of Blood and Marrow Transplantation. 12: 789-791. PMID 16785069 DOI: 10.1016/j.bbmt.2006.03.008  1
2006 Ozer N, Haliloglu T, Schiffer CA. Substrate specificity in HIV-1 protease by a biased sequence search method. Proteins. 64: 444-56. PMID 16741993 DOI: 10.1002/Prot.21023  1
2006 Larson RA, Stone RM, Mayer RJ, Schiffer CA. Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3556s-63s. PMID 16740785 DOI: 10.1158/1078-0432.CCR-06-9001  1
2006 Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, et al. 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline Journal of Clinical Oncology. 24: 3187-3205. PMID 16682719 DOI: 10.1200/JCO.2006.06.4451  1
2006 Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 108: 419-25. PMID 16609072 DOI: 10.1182/blood-2005-10-4149  1
2006 Prabu-Jeyabalan M, King NM, Nalivaika EA, Heilek-Snyder G, Cammack N, Schiffer CA. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease. Antimicrobial Agents and Chemotherapy. 50: 1518-21. PMID 16569872 DOI: 10.1128/Aac.50.4.1518-1521.2006  1
2006 Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. Journal of Virology. 80: 3607-16. PMID 16537628 DOI: 10.1128/Jvi.80.7.3607-3616.2006  1
2006 Kolli M, Lastere S, Schiffer CA. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology. 347: 405-9. PMID 16430939 DOI: 10.1016/J.Virol.2005.11.049  1
2006 Patel BB, Mohamed AN, Schiffer CA. "Acute myelogenous leukemia like" translocations in CML blast crisis: Two new cases of inv(16)/t(16;16) and a review of the literature Leukemia Research. 30: 225-232. PMID 16076492 DOI: 10.1016/j.leukres.2005.06.008  1
2006 Schiffer CA. Granulocyte transfusion therapy 2006: The comeback kid? Medical Mycology. 44: 383-386. DOI: 10.1080/13693780600752499  1
2005 Schiffer CA, Estey EH. "3+7" therapy for the treatment of acute myeloid leukemia Clinical Advances in Hematology and Oncology. 3: 127-132+141. PMID 16166981  1
2005 Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5705-17. PMID 16110030 DOI: 10.1200/Jco.2005.15.610  1
2005 Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. PTEN enters the nucleus by diffusion. Journal of Cellular Biochemistry. 96: 221-34. PMID 16088943 DOI: 10.1002/Jcb.20525  1
2005 Schiffer CA. Use of myeloid growth factors for patients with febrile neutropenia: Plus ça change, plus c'est la même chose Pediatric Blood and Cancer. 45: 242-243. PMID 15983983 DOI: 10.1002/pbc.20449  1
2005 Surleraux DL, de Kock HA, Verschueren WG, Pille GM, Maes LJ, Peeters A, Vendeville S, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Design of HIV-1 protease inhibitors active on multidrug-resistant virus. Journal of Medicinal Chemistry. 48: 1965-73. PMID 15771440 DOI: 10.1021/Jm049454N  1
2005 Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. Journal of Medicinal Chemistry. 48: 1813-22. PMID 15771427 DOI: 10.1021/Jm049560P  1
2005 Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy Leukemia Research. 29: 463-465. PMID 15725482 DOI: 10.1016/j.leukres.2004.09.004  1
2005 Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients Blood. 105: 4106-4114. PMID 15692069 DOI: 10.1182/Blood-2003-08-2724  1
2005 Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 105: 3420-7. PMID 15572587 DOI: 10.1182/blood-2004-08-2977  1
2005 Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, ... Schiffer CA, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 482-93. PMID 15534356 DOI: 10.1200/JCO.2005.06.090  1
2005 Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 105: 49-53. PMID 15138165 DOI: 10.1182/blood-2004-03-0796  1
2005 Schiffer CA. Divide and conquer: Stomping leukemia cells by stimulating them to grow Blood. 106: 3-4. DOI: 10.1182/blood-2005-04-1497  1
2005 Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. A representation of a possible intermediate step during substrate recognition of HIV-1 protease: crystal structures of substrate bound enzyme exhibiting a novel flap conformation Acta Crystallographica Section a Foundations of Crystallography. 61: c196-c196. DOI: 10.1107/S0108767305091634  0.01
2005 Hoffman NG, Schiffer CA, Swanstrom R. Erratum to “Covariation of amino acid positions in HIV-1 protease” [Virology 314 (2003) 536–548] Virology. 331: 206-207. DOI: 10.1016/J.Virol.2004.10.029  0.01
2004 Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrobial Agents and Chemotherapy. 48: 4864-8. PMID 15561868 DOI: 10.1128/Aac.48.12.4864-4868.2004  1
2004 Bagby GC, Lipton JM, Sloand EM, Schiffer CA. Marrow failure. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 318-36. PMID 15561690 DOI: 10.1182/asheducation-2004.1.318  1
2004 Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. Journal of Virology. 78: 12446-54. PMID 15507631 DOI: 10.1128/Jvi.78.22.12446-12454.2004  1
2004 King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chemistry & Biology. 11: 1333-8. PMID 15489160 DOI: 10.1016/S1074-5521(04)00243-1  1
2004 King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Béthune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. Journal of Virology. 78: 12012-21. PMID 15479840 DOI: 10.1128/Jvi.78.21.12012-12021.2004  1
2004 Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 100: 1438-48. PMID 15042678 DOI: 10.1002/cncr.20143  1
2004 Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 103: 4036-42. PMID 14976037 DOI: 10.1182/blood-2003-09-3118  1
2004 Marcucci G, Mrózek K, Ruppert AS, Maharry K, Kolitz JE, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study. Blood. 104: 2017-2017. DOI: 10.1182/Blood.V104.11.2017.2017  0.01
2003 Schiffer C, Hermans J. Promise of advances in simulation methods for protein crystallography: implicit solvent models, time-averaging refinement, and quantum mechanical modeling. Methods in Enzymology. 374: 412-61. PMID 14696384 DOI: 10.1016/S0076-6879(03)74019-1  1
2003 Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 4642-9. PMID 14673054 DOI: 10.1200/JCO.2003.04.036  1
2003 Larson RA, Daley GQ, Schiffer CA, Porcu P, Pui CH, Marie JP, Steelman LS, Bertrand FE, McCubrey JA. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002 Leukemia. 17: 2358-2382. PMID 14562120 DOI: 10.1038/sj.leu.2403156  1
2003 Hoffman NG, Schiffer CA, Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology. 314: 536-48. PMID 14554082 DOI: 10.1016/S0042-6822(03)00484-7  1
2003 Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia New England Journal of Medicine. 349: 727-729. PMID 12930923 DOI: 10.1056/NEJMp030076  1
2003 Zonder JA, Schiffer CA. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate Current Hematology Reports. 2: 57-64. PMID 12901155  1
2003 Dan ME, Schiffer CA. Strategies for managing refractoriness to platelet transfusions Current Hematology Reports. 2: 158-164. PMID 12901147  1
2003 Kurt N, Haliloglu T, Schiffer CA. Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. Biophysical Journal. 85: 853-63. PMID 12885633 DOI: 10.1016/S0006-3495(03)74525-1  1
2003 Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment Clinical Cancer Research. 9: 2092-2097. PMID 12796373  1
2003 Kurt N, Scott WR, Schiffer CA, Haliloglu T. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: a structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. Proteins. 51: 409-22. PMID 12696052 DOI: 10.1002/Prot.10350  1
2003 Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leukemia & Lymphoma. 44: 39-48. PMID 12691141 DOI: 10.1080/1042819021000040260  1
2003 Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations Clinical Cancer Research. 9: 1333-1337. PMID 12684401  1
2003 Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA. Management of patients refractory to platelet transfusion. Archives of Pathology & Laboratory Medicine. 127: 409-14. PMID 12683867 DOI: 10.1038/Sj.Leu.2402075  1
2003 Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL Leukemia. 17: 691-699. PMID 12682626 DOI: 10.1038/Sj.Leu.2402879  1
2003 Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. Journal of Virology. 77: 4836-47. PMID 12663790 DOI: 10.1128/Jvi.77.8.4836-4847.2003  1
2003 Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 97: 1471-80. PMID 12627512 DOI: 10.1002/Cncr.11219  1
2003 Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens? Better doctors? Both? Journal of Clinical Oncology. 21: 760-761. PMID 12610169 DOI: 10.1200/JCO.2003.11.116  1
2003 Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia. 17: 323-7. PMID 12592330 DOI: 10.1038/Sj.Leu.2402752  1
2003 Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. Journal of Virology. 77: 1306-15. PMID 12502847 DOI: 10.1128/Jvi.77.2.1306-1315.2003  1
2003 Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101: 6-14. PMID 12393429 DOI: 10.1182/blood-2002-04-1258  1
2003 Buchholz DH, Schiffer CA, Wiernik PH, Betts SW, Reilly JA. Granulocyte harvest for transfusion: donor response to repeated leukapheresis. Transfusion. 15: 96-106. PMID 1118886 DOI: 10.1046/J.1537-2995.1975.15275122816.X  1
2002 Zonder JA, Keating M, Schiffer CA. Chronic lymphocytic leukemia presenting in association with aplastic anemia American Journal of Hematology. 71: 323-327. PMID 12447965 DOI: 10.1002/ajh.10226  1
2002 Schonhoff CM, Daou MC, Jones SN, Schiffer CA, Ross AH. Nitric oxide-mediated inhibition of Hdm2-p53 binding. Biochemistry. 41: 13570-4. PMID 12427017 DOI: 10.1021/Bi026262Q  1
2002 Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 100: 4298-302. PMID 12393590 DOI: 10.1182/blood-2002-02-0632  1
2002 Liu H, Radhakrishnan P, Magoun L, Prabu M, Campellone KG, Savage P, He F, Schiffer CA, Leong JM. Point mutants of EHEC intimin that diminish Tir recognition and actin pedestal formation highlight a putative Tir binding pocket. Molecular Microbiology. 45: 1557-73. PMID 12354225 DOI: 10.1046/J.1365-2958.2002.03137.X  1
2002 Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. Journal of Virology. 76: 10226-33. PMID 12239298 DOI: 10.1128/Jvi.76.20.10226-10233.2002  1
2002 Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2812-9. PMID 12231521  1
2002 Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, Hines JD, Shepherd L, Larson RA, Schiffer CA. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3878-84. PMID 12228208 DOI: 10.1200/JCO.2002.08.128  1
2002 Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100: 1224-32. PMID 12149202  1
2002 Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemotherapy and Pharmacology. 50: 37-45. PMID 12111110 DOI: 10.1007/s00280-002-0443-5  1
2002 Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study Journal of Clinical Oncology. 20: 2441-2452. PMID 12011121 DOI: 10.1200/JCO.2002.04.044  1
2002 Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2429-40. PMID 12011120 DOI: 10.1200/JCO.2002.04.117  1
2002 Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (London, England : 1993). 10: 369-81. PMID 12005435 DOI: 10.1016/S0969-2126(02)00720-7  1
2002 Schiffer CA. Postremission therapy in older adults with acute myeloid leukemia: An opportunity for new drug development Leukemia. 16: 745-747. PMID 11960360 DOI: 10.1038/Sj.Leu.2402487  1
2002 Schiffer C, Ultsch M, Walsh S, Somers W, De Vos AM, Kossiakoff A. Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: Evidence for strong structural coupling between receptor binding sites Journal of Molecular Biology. 316: 277-289. PMID 11851338 DOI: 10.1006/Jmbi.2001.5348  1
2002 King NM, Melnick L, Prabu-Jeyabalan M, Nalivaika EA, Yang SS, Gao Y, Nie X, Zepp C, Heefner DL, Schiffer CA. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Science : a Publication of the Protein Society. 11: 418-29. PMID 11790852 DOI: 10.1110/Ps.25502  1
2002 Schiffer CA. Leukemia Current Opinion in Oncology. 14: 1-2. DOI: 10.1097/00001622-200201000-00001  1
2001 Schiffer CA. Signal transduction inhibition: Changing paradigms in cancer care Seminars in Oncology. 28: 34-39. PMID 11740805  1
2001 Schiffer CA. Acute myeloid leukemia in adults: Where do we go from here? Cancer Chemotherapy and Pharmacology. 48: S45-S52. PMID 11587367 DOI: 10.1007/s002800100304  1
2001 Schiffer CA. Seminars in oncology Seminars in Oncology. 28: 1-2.  1
2000 Scott WR, Schiffer CA. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure (London, England : 1993). 8: 1259-65. PMID 11188690 DOI: 10.1016/S0969-2126(00)00537-2  0.01
2000 Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. Journal of Molecular Biology. 301: 1207-20. PMID 10966816 DOI: 10.1006/Jmbi.2000.4018  0.01
1999 Schiffer CA, van Gunsteren WF. Accessibility and order of water sites in and around proteins: A crystallographic time-averaging study. Proteins. 36: 501-11. PMID 10450092 DOI: 10.1002/(Sici)1097-0134(19990901)36:4<501::Aid-Prot14>3.0.Co;2-1  1
1999 Wetzler M, Dodge RK, Mrózek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Beau MML, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 93: 3983-3993. DOI: 10.1182/Blood.V93.11.3983.411K14_3983_3993  1
1998 Kornblith AB, Herndon JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 9: 297-306. PMID 9602264 DOI: 10.1023/A:1008297130258  1
1998 Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 12: 660-5. PMID 9593262 DOI: 10.1038/Sj.Leu.2401007  1
1998 Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrózek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 12: 317-25. PMID 9529125 DOI: 10.1038/Sj.Leu.2400933  1
1998 Lee EJ, George SL, Amrein PC, Paciucci PA, Allen SL, Schiffer CA. An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: Results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B Leukemia. 12: 139-143. PMID 9519774 DOI: 10.1038/Sj.Leu.2400905  1
1997 Alonsozana ELC, Stamberg J, Kumar D, Jaffe ES, Medeiros LJ, Frantz C, Schiffer CA, O'Connell BA, Kerman S, Stass SA, Abruzzo L. Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic γδ T cell lymphoma Leukemia. 11: 1367-1372. PMID 9264394 DOI: 10.1038/Sj.Leu.2400742  0.01
1997 Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 466-75. PMID 9053467 DOI: 10.1200/Jco.1997.15.2.466  1
1997 Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, Le Beau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 26-36. PMID 8996121 DOI: 10.1200/Jco.1997.15.1.26  1
1996 Peng JW, Schiffer CA, Xu P, van Gunsteren WF, Ernst RR. Investigations of peptide hydration using NMR and molecular dynamics simulations: A study of effects of water on the conformation and dynamics of antamanide. Journal of Biomolecular Nmr. 8: 453-76. PMID 20859779 DOI: 10.1007/Bf00228147  1
1996 Schiffer CA, van Gunsteren WF. Structural stability of disulfide mutants of basic pancreatic trypsin inhibitor: a molecular dynamics study. Proteins. 26: 66-71. PMID 8880930 DOI: 10.1002/(Sici)1097-0134(199609)26:1<66::Aid-Prot6>3.0.Co;2-E  1
1996 Schiffer CA, Dötsch V. The role of protein-solvent interactions in protein unfolding Current Opinion in Biotechnology. 7: 428-432. PMID 8768902 DOI: 10.1016/S0958-1669(96)80119-4  1
1995 Schiffer CA, Gros P, van Gunsteren WF. Time-averaging crystallographic refinement: possibilities and limitations using alpha-cyclodextrin as a test system. Acta Crystallographica. Section D, Biological Crystallography. 51: 85-92. PMID 15299339 DOI: 10.1107/S0907444994007158  1
1995 Schiffer CA, Clifton IJ, Davisson VJ, Santi DV, Stroud RM. Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Biochemistry. 34: 16279-87. PMID 8845352 DOI: 10.1021/Bi00050A007  1
1995 Van Gunsteren WF, Hünenberger PH, Kovacs H, Mark AE, Schiffer CA. Investigation of protein unfolding and stability by computer simulation. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 348: 49-59. PMID 7770486 DOI: 10.1098/Rstb.1995.0045  1
1995 Schiffer CA, Dötsch V, Wüthrich K, van Gunsteren WF. Exploring the role of the solvent in the denaturation of a protein: a molecular dynamics study of the DNA binding domain of the 434 repressor. Biochemistry. 34: 15057-67. PMID 7578118 DOI: 10.1021/Bi00046A011  1
1995 Bisang C, Weber C, Inglis J, Schiffer CA, van Gunsteren WF, Jelesarov I, Bosshard HR, Robinson JA. Stabilization of Type-I .beta.-Turn Conformations in Peptides Containing the NPNA-Repeat Motif of the Plasmodium falciparum Circumsporozoite Protein by Substituting Proline for (S)-.alpha.-Methylproline Journal of the American Chemical Society. 117: 7904-7915. DOI: 10.1021/Ja00135A008  1
1994 Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. The New England Journal of Medicine. 331: 896-903. PMID 8078551 DOI: 10.1056/Nejm199410063311402  1
1994 Greene PJ, Yu PL, Zhao J, Schiffer CA, Santi D. Expression, purification, and characterization of thymidylate synthase from Lactococcus lactis. Protein Science : a Publication of the Protein Society. 3: 1114-6. PMID 7920258 DOI: 10.1002/Pro.5560030715  0.01
1994 van Gunsteren WF, Brunne RM, Gros P, van Schaik RC, Schiffer CA, Torda AE. Accounting for molecular mobility in structure determination based on nuclear magnetic resonance spectroscopic and X-ray diffraction data. Methods in Enzymology. 239: 619-54. PMID 7530320 DOI: 10.1016/S0076-6879(94)39024-X  1
1994 Schiffer CA, Huber R, Wüthrich K, van Gunsteren WF. Simultaneous refinement of the structure of BPTI against NMR data measured in solution and X-ray diffraction data measured in single crystals. Journal of Molecular Biology. 241: 588-99. PMID 7520085 DOI: 10.1006/Jmbi.1994.1533  1
1994 Neubauer A, Dodge R, George S, Davey F, Silver R, Schiffer C, Mayer R, Ball E, Wurster-Hill D, Bloomfield C. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia Blood. 83: 1603-1611. DOI: 10.1182/Blood.V83.6.1603.Bloodjournal8361603  1
1993 Cooper MR, Dear K, McIntyre OR, Ozer H, Ellerton J, Canellos G, Bernhardt B, Duggan D, Faragher D, Schiffer C. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 11: 155-160. PMID 8418228 DOI: 10.1200/Jco.1993.11.1.155  1
1993 Schiffer CA, Caldwell JW, Kollman PA, Stroud RM. Protein Structure Prediction with a Combined Solvation Free Energy-Molecular Mechanics Force Field Molecular Simulation. 10: 121-149. DOI: 10.1080/08927029308022162  0.04
1992 Schiffer CA, Caldwell JW, Stroud RM, Kollman PA. Inclusion of solvation free energy with molecular mechanics energy: alanyl dipeptide as a test case. Protein Science : a Publication of the Protein Society. 1: 396-400. PMID 1304346 DOI: 10.1002/Pro.5560010311  1
1992 Schiffer CA, Stone RM, Peterson BA, Moore J. CALGB studies with hematopoietic growth factors in patients with AML Leukemia and Lymphoma. 7: 65. DOI: 10.3109/10428199209058664  1
1991 Schiffer CA, Davisson VJ, Santi DV, Stroud RM. Crystallization of human thymidylate synthase. Journal of Molecular Biology. 219: 161-3. PMID 2038053 DOI: 10.1016/0022-2836(91)90558-N  1
1991 Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, Bloomfield CD, Holland JF. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B Journal of Clinical Oncology. 9: 2002-2015. PMID 1941059 DOI: 10.1200/Jco.1991.9.11.2002  1
1991 Dillman R, Davis R, Green M, Weiss R, Gottlieb A, Caplan S, Kopel S, Preisler H, McIntyre O, Schiffer C. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B Blood. 78: 2520-2526. DOI: 10.1182/Blood.V78.10.2520.Bloodjournal78102520  0.01
1991 Schiffer C. Prevention Of Alloimmunization Against Platelets Blood. 77: 1-4. DOI: 10.1182/Blood.V77.1.1.Bloodjournal7711  1
1990 Schiffer CA, Caldwell JW, Kollman PA, Stroud RM. Prediction of homologous protein structures based on conformational searches and energetics. Proteins. 8: 30-43. PMID 2217162 DOI: 10.1002/Prot.340080107  1
1989 Karesh JW, Goldman EJ, Reck K, Kelman SE, Lee EJ, Schiffer CA. A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1528-32. PMID 2778482 DOI: 10.1200/Jco.1989.7.10.1528  1
1989 Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion. 29: 384-389. PMID 2660333 DOI: 10.1046/J.1537-2995.1989.29589284135.X  1
1989 Davey FR, Davis RB, MacCallum JM, Nelson DA, Mayer RJ, Ball ED, Griffin JD, Schiffer CA, Bloomfield CD. Morphologic and cytochemical characteristics of acute promyelocytic leukemia. American Journal of Hematology. 30: 221-7. PMID 2539013 DOI: 10.1002/Ajh.2830300406  1
1988 O'Connell B, Lee EJ, Schiffer CA. The value of 10-minute posttransfusion platelet counts Transfusion. 28: 66-67. PMID 3341070 DOI: 10.1046/J.1537-2995.1988.28188127957.X  1
1987 Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. Journal of Clinical Oncology. 5: 1364-1372. PMID 3625254 DOI: 10.1200/Jco.1987.5.9.1364  1
1987 Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion. 27: 245-247. PMID 3590287 DOI: 10.1046/J.1537-2995.1987.27387235630.X  1
1986 Hogge DE, Thompson BW, Schiffer CA. Platelet storage for 7 days in second-generation blood bags. Transfusion. 26: 131-5. PMID 3952787 DOI: 10.1046/J.1537-2995.1986.26286152900.X  0.01
1986 Griffin J, Davis R, Nelson D, Davey F, Mayer R, Schiffer C, McIntyre O, Bloomfield C. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 68: 1232-1241. DOI: 10.1182/Blood.V68.6.1232.Bloodjournal6861232  1
1986 Ross D, Joneckis C, Schiffer C. Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia. Blood. 68: 83-88. DOI: 10.1182/Blood.V68.1.83.83  1
1986 Ross D, Thompson B, Joneckis C, Akman S, Schiffer C. Metabolism of ara-C by blast cells from patients with ANLL. Blood. 68: 76-82. DOI: 10.1182/Blood.V68.1.76.Bloodjournal68176  1
1986 Schiffer C, Lee E, Ness P, Reilly J. Clinical evaluation of platelet concentrates stored for one to five days Blood. 67: 1591-1594. DOI: 10.1182/Blood.V67.6.1591.Bloodjournal6761591  0.01
1985 Sobol R, Royston I, LeBien T, Minowada J, Anderson K, Davey F, Cuttner J, Schiffer C, Ellison R, Bloomfield C. Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies Blood. 65: 730-735. DOI: 10.1182/Blood.V65.3.730.Bloodjournal653730  0.01
1984 Schiffer C, Hogge D, Aisner J, Dutcher J, Lee E, Papenberg D. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients Blood. 64: 937-940. DOI: 10.1182/Blood.V64.4.937.937  0.01
1984 Hogge D, Dutcher J, Aisner J, Schiffer C. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients Blood. 64: 253-256. DOI: 10.1182/Blood.V64.1.253.Bloodjournal641253  1
1983 Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH. Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion. 23: 286-9. PMID 6879666 DOI: 10.1046/J.1537-2995.1983.23483276859.X  0.01
1983 Schiffer C, Young V. Detection of platelet antibodies using a micro-enzyme-linked immunosorbent assay (ELISA). Blood. 61: 311-317. DOI: 10.1182/Blood.V61.2.311.311  1
1981 Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose- response relationship Blood. 57: 395-398. DOI: 10.1182/Blood.V57.3.395.Bloodjournal573395  1
1979 Daly PA, Schiffer CA, Aisner J, Wiernik PH. A comparison of platelets prepared by the Haemonetics Model 30 and multiunit bag plateletpheresis. Transfusion. 19: 778-781. PMID 524435 DOI: 10.1046/J.1537-2995.1979.19680104109.X  1
1979 Daly P, Schiffer C, Aisner J, Wiernik P. Successful transfusion of platelets cryopreserved for more than 3 years. Blood. 54: 1023-1027. DOI: 10.1182/Blood.V54.5.1023.Bloodjournal5451023  1
Show low-probability matches.